138 related articles for article (PubMed ID: 9024246)
1. Acute effects of bromocriptine, cyproheptadine, and valproic acid on plasma adrenocorticotropin secretion in Nelson's syndrome.
Mercado-Asis LB; Yanovski JA; Tracer HL; Chik CL; Cutler GB
J Clin Endocrinol Metab; 1997 Feb; 82(2):514-7. PubMed ID: 9024246
[TBL] [Abstract][Full Text] [Related]
2. Effects of bromocriptine and cyproheptadine on basal and corticotropin-releasing factor (CRF)-induced ACTH release in a patient with Nelson's syndrome.
Hirata Y; Nakashima H; Uchihashi M; Tomita M; Fujita T; Ikeda M
Endocrinol Jpn; 1984 Oct; 31(5):619-26. PubMed ID: 6097444
[TBL] [Abstract][Full Text] [Related]
3. ACTH responses to somatostatin, valproic acid and dexamethasone in Nelson's syndrome.
Kasperlik-Załuska AA; Zgliczyński W; Jeske W; Zdunowski P
Neuro Endocrinol Lett; 2005 Dec; 26(6):709-12. PubMed ID: 16380696
[TBL] [Abstract][Full Text] [Related]
4. Nelson's syndrome: complete remission with cabergoline but not with bromocriptine or cyproheptadine treatment.
Casulari LA; Naves LA; Mello PA; Pereira Neto A; Papadia C
Horm Res; 2004; 62(6):300-5. PubMed ID: 15557761
[TBL] [Abstract][Full Text] [Related]
5. The effect of cyproheptadine and/or bromocriptine on plasma ACTH levels in patients cured of Cushing's disease by bilateral adrenalectomy.
Whitehead HM; Beacom R; Sheridan B; Atkinson AB
Clin Endocrinol (Oxf); 1990 Feb; 32(2):193-201. PubMed ID: 2161298
[TBL] [Abstract][Full Text] [Related]
6. Cyproheptadine treatment of Nelson's syndrome: restoration of plasma ACTH circadian periodicity and reversal of response to TRF.
Krieger DT; Condon EM
J Clin Endocrinol Metab; 1978 Feb; 46(2):349-52. PubMed ID: 220278
[TBL] [Abstract][Full Text] [Related]
7. The effect of magnesium valproate on plasma ACTH concentrations in Nelson's syndrome.
Kasperlik-Załuska A; Migdalska B; Jeske W; Drac-Kaniewska J; Wiśniewska-Woźniak T
Acta Med Pol; 1989; 30(1-2):9-15. PubMed ID: 2562233
[TBL] [Abstract][Full Text] [Related]
8. The evaluation of sodium valproate in the treatment of Nelson's syndrome.
Dornhorst A; Jenkins JS; Lamberts SW; Abraham RR; Wynn V; Beckford U; Gillham B; Jones MT
J Clin Endocrinol Metab; 1983 May; 56(5):985-91. PubMed ID: 6300181
[TBL] [Abstract][Full Text] [Related]
9. Profound amplification of secretory-burst mass and anomalous regularity of ACTH secretory process in patients with Nelson's syndrome compared with Cushing's disease.
van Aken MO; Pereira AM; van den Berg G; Romijn JA; Veldhuis JD; Roelfsema F
Clin Endocrinol (Oxf); 2004 Jun; 60(6):765-72. PubMed ID: 15163342
[TBL] [Abstract][Full Text] [Related]
10. Corticotropin-releasing hormone (CRH) stimulation in Nelson's syndrome: response of adrenocorticotropin secretion to pulse injection and continuous infusion of CRH.
Oldfield EH; Schulte HM; Chrousos GP; Gold PW; Benker G; Peterson RE; Cutler GB; Loriaux DL
J Clin Endocrinol Metab; 1986 May; 62(5):1020-6. PubMed ID: 3007552
[TBL] [Abstract][Full Text] [Related]
11. Effects of valproic acid, naloxone and hydrocortisone in Nelson's syndrome and cushing's disease.
Elias AN; Gwinup G; Valenta LJ
Clin Endocrinol (Oxf); 1981 Aug; 15(2):151-4. PubMed ID: 6273025
[TBL] [Abstract][Full Text] [Related]
12. The effect of sodium valproate on plasma ACTH and cortisol concentrations in Cushing's disease and Nelson's syndrome.
Kasperlik-Załuska A; Drac-Kaniewska J; Migdalska B; Jeske W; Wiśniewska-Woźniak T
Endokrynol Pol; 1988; 39(5):245-52. PubMed ID: 2855625
[No Abstract] [Full Text] [Related]
13. Effectiveness of cyproheptadine in decreasing plasma ACTH concentrations in Nelson's syndrome.
Krieger DT; Luria M
J Clin Endocrinol Metab; 1976 Nov; 43(5):1179-82. PubMed ID: 186479
[TBL] [Abstract][Full Text] [Related]
14. Sustained remission of Nelson's syndrome after stopping cyproheptadine treatment.
Aronin N; Krieger DT
N Engl J Med; 1980 Feb; 302(8):453-5. PubMed ID: 6243392
[No Abstract] [Full Text] [Related]
15. The effect of sodium valproate in Cushing's disease, Nelson's syndrome and Addison's disease.
Reincke M; Allolio B; Kaulen D; Jaursch-Hancke C; Winkelmann W
Klin Wochenschr; 1988 Aug; 66(15):686-9. PubMed ID: 2845188
[TBL] [Abstract][Full Text] [Related]
16. Effect of cyproheptadine, desmethylcyproheptadine, gamma-amino-butyric acid and sodium valproate on adrenocorticotrophin secretion by cultured pituitary tumour cells from three patients with Nelson's syndrome.
Lamberts SW; Verleun T; Bons EG; Uitterlinden P; Oosterom R
J Endocrinol; 1983 Mar; 96(3):401-6. PubMed ID: 6300275
[TBL] [Abstract][Full Text] [Related]
17. Long-term treatment of Nelson's syndrome with sodium valproate.
Kelly W; Adams JE; Laing I; Longson D; Davies D
Clin Endocrinol (Oxf); 1988 Feb; 28(2):195-204. PubMed ID: 2844446
[TBL] [Abstract][Full Text] [Related]
18. Lack of ACTH lowering effect of sodium valproate in patients with ACTH hypersecretion.
Loli P; Berselli ME; Frascatani F; Muratori F; Tagliaferri M
J Endocrinol Invest; 1984 Apr; 7(2):93-6. PubMed ID: 6327800
[TBL] [Abstract][Full Text] [Related]
19. Unaltered stimulation of pituitary adrenocorticotrophin secretion by corticotrophin-releasing factor following sodium valproate administration in a patient with Nelson's syndrome.
Gomi M; Iida S; Itoh Y; Moriwaki K; Kanayama S; Namba M; Tarui S
Clin Endocrinol (Oxf); 1985 Aug; 23(2):123-7. PubMed ID: 2996808
[TBL] [Abstract][Full Text] [Related]
20. Sustained improvements in plasma ACTH and clinical status in a patient with Nelson's syndrome treated with pasireotide LAR, a multireceptor somatostatin analog.
Katznelson L
J Clin Endocrinol Metab; 2013 May; 98(5):1803-7. PubMed ID: 23539733
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
